Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24783669 | 0.83 | EPHX2 (0.38) | NCF1LMNAPLGPLATEPHX2 | |
| SCHEMBL3536174 | 0.83 | EPHX2 (0.38) | NCF1LMNAPLGPLATEPHX2 | |
| SCHEMBL21424008 | 0.80 | NCF1 (0.48) | NCF1LMNAPLGPLATEPHX2 | |
| SCHEMBL13636377 | 0.79 | — | — | |
| SCHEMBL16191326 | 0.78 | — | — | |
| SCHEMBL11903679 | 0.77 | CYP1A2 (0.48) | LMNAMAPK1HTTCYP1A2 | |
| SCHEMBL18634257 | 0.76 | LMNA (0.31) | LMNAMAPK1HTT | |
| SCHEMBL12806088 | 0.76 | — | — | |
| SCHEMBL12805515 | 0.74 | SIGMAR1 (0.30) | SIGMAR1 | |
| SCHEMBL12805708 | 0.74 | SIGMAR1 (0.30) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | SIGMAR1 1749/4885NCF1 4137/4885LMNA 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.